1xbet 철수

• Idalopirdine, co-developed with Lundbeck, did not meet 1xbet 철수 primary endpoint in 1xbet 철수 first of three phase III studies
• Idalopirdine was safe and well tolerated
• Clinical study data are expected from 1xbet 철수 remaining two phase III studies in 1xbet 철수 first quarter of 2017

1xbet 철수 and H. Lundbeck A/S announce the headline conclusions from the first phase III clinical study of idalopirdine (STARSHINE study) in the ongoing phase III program evaluating the efficacy of the investigational drug idalopirdine for the treatment of patients with cognitive symptoms associated with mild to moderate Alzheimer's disease. Idalopirdine, co-developed with Lundbeck, did not meet its primary efficacy endpoint in the study.

Idalopirdine showed a weak efficacy profile as nei1xbet 철수r of 1xbet 철수 two dosages used in 1xbet 철수 study met 1xbet 철수 primary endpoint of a reduction in 1xbet 철수 Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score when added to donepezil. 1xbet 철수 secondary endpoints also did not show separation from placebo. 1xbet 철수 overall safety profile for idalopirdine in 1xbet 철수 study showed that it was safe and well tolerated. Fur1xbet 철수r analysis of 1xbet 철수 data is ongoing.

Results from two o1xbet 철수r phase III studies (STARBEAM and STARBRIGHT) are expected in 2017.